Role of Cytochrome P450s in Inflammation

Advances in Pharmacology

Volumn 74, Issue , 2015, Pages 163-192

  Christmas, Peter ^a  

^a RADFORD UNIVERSITY   (United States)

Author keywords

20 Hydroxyeicosatetraenoic acid; Cytochrome P450; Epoxyeicosatrienoic acid; Inflammation; Leukotriene B4; Pharmacokinetics; Soluble epoxide hydrolase

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 EPOXYGENASE; CYTOCHROME P450 HYDROXYLASE; OXYGENASE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CYTOKINE;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL STUDY; ENZYME ACTIVITY; HUMAN; INFLAMMATION; LIVER CELL; METABOLIC SYNDROME X; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; HEPATOCYTES; HUMANS; INFLAMMATION;

EID: 84933566930     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2015.03.005     Document Type: Chapter

References (151)

1. Abraham N.G., Sodhi K., Silvis A.M., Vanella L., Favero G., Rezzani R., et al. CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high fat diet by reprogramming adipocyte differentiation. Hypertension 2014, 64(6):1352-1361.
2. Aitken A.E., Morgan E.T. Gene-specific effects of inflammatory cytokines on cytochrome P4502C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metabolism and Disposition 2007, 35(9):1687-1693.
3. Aitken A.E., Richardson T.A., Morgan E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annual Review of Pharmacology and Toxicology 2006, 46:123-149.
4. Alexanian A., Sorokin A. Targeting 20-HETE producing enzymes in cancer-Rationale, pharmacology, and clinical potential. OncoTargets and Therapy 2013, 6:243-255.
5. Alonso-Galicia M., Falck J.R., Reddy K.M., Roman R.J. 20-HETE agonists and antagonists in the renal circulation. American Journal of Physiology. Renal Physiology 1999, 277(5):F790-F796.
6. 1 in human liver cells: A regulation of the 20-HETE synthesis. The Journal of Lipid Research 2008, 49(10):2135-2141.
7. Anwar-Mohamed A., Zordoky B.N., Aboutabl M.E., El-Kadi A.O. Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacological Research 2010, 61(5):410-418.
8. Ashino T., Arima Y., Shioda S., Iwakura Y., Numazawa S., Yoshida T. Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. European Journal of Pharmacology 2007, 558(1-3):199-207.
9. Askari A.A., Thomson S., Edin M.L., Lih F.B., Zeldin D.C., Bishop-Bailey D. Basal and inducible anti-inflammatory epoxygenase activity in endothelial cells. Biochemical and Biophysical Research Communications 2014, 446(2):633-637.
10. Astarita G., Kendall A.C., Dennis E.A., Nicolaou A. Targeted lipidomic strategies for oxygenated metabolites of polyunsaturated fatty acids. Biochimica et Biophysica Acta 2015, 1851(4):456-468.
11. Bettaieb A., Nagata N., AbouBechara D., Chahed S., Morisseau C., Hammock B.D., et al. Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue. The Journal of Biological Chemistry 2013, 288(20):14189-14199.
12. Bystrom J., Thomson S.J., Johansson J., Edin M.L., Zeldin D.C., Gilroy D.W., et al. Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: A role for CYP2J2 deficiency in the pathogenesis of Crohn's disease?. PLoS One 2013, 8(9). e75107.
13. Caesar R., Fak F., Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. Journal of Internal Medicine 2010, 268(4):320-328.
14. Campbell W.B., Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflügers Archiv 2010, 459(6):881-895.
15. Carcillo J.A., Doughty L., Kofos D., Frye R.F., Kaplan S.S., Sasser H., et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Medicine 2003, 29(6):980-984.
16. Chaluvadi M.R., Kinloch R.D., Nyagode B.A., Richardson T.A., Raynor M.J., Sherman M., et al. Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of Citrobacter rodentium. Drug Metabolism and Disposition 2009, 37(2):366-374.
17. Chaluvadi M.R., Nyagode B.A., Kinloch R.D., Morgan E.T. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically-induced inflammatory bowel disease. Biochemical Pharmacology 2009, 77(3):464-471.
18. Chassaing B., Gewirtz A.T. Gut microbiota, low-grade inflammation, and metabolic syndrome. Toxicologic Pathology 2014, 42(1):49-53.
19. Chaudhari N., Talwar P., Parimisetty A., Lefebvre d'Hellencourt C., Ravanan P. A molecular web: Endoplasmic reticulum stress, inflammation, and oxidative stress. Frontiers in Cellular Neuroscience 2014, 8:213.
20. Chen L., Ackerman R., Guo A.M. 20-HETE in neovascularization. Prostaglandins & Other Lipid Mediators 2012, 98(3-4):63-68.
21. Chen L., Ackerman R., Saleh M., Gotlinger K.H., Kessler M., Mendelowitz L.G., et al. 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. Journal of Pharmacology and Experimental Therapeutics 2014, 348(3):442-451.
22. Chen C., Han Y.-H., Yang Z., Rodrigues A.D. Effect of interferon-α2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes. Xenobiotica 2011, 41(6):476-485.
23. Chen Y.L., Le Vraux V., Leneveu A., Dreyfus F., Stheneur A., Florentin I., et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clinical Pharmacology & Therapeutics 1994, 55(6):649-660.
24. Chen C., Wang D.W. CYP epoxygenase derived EETs: From cardiovascular protection to human cancer therapy. Current Topics in Medicinal Chemistry 2013, 13(12):1454-1469.
25. Chen C., Wei X., Rao X., Wu J., Yang S., Chen F., et al. Cytochrome P450 2J2 is highly expressed in hematologic malignant disease and promotes tumor cell growth. The Journal of Pharmacology and Experimental Therapeutics 2011, 336(2):344-355.
26. Chen D., Whitcomb R., MacIntyre E., Tran V., Do Z.N., Sabry J., et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-doses in healthy human subjects. The Journal of Clinical Pharmacology 2012, 52(3):319-328.
27. Chen G., Xu R., Zhang S., Wang Y., Wang P., Edin M.L., et al. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice. American Journal of Physiology. Endocrinology and Metabolism 2015, 308(2):E97-E110.
28. Cheng J., Edin M.L., Hoopes S.L., Li H., Bradbury J.A., Graves J.P., et al. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. The FASEB Journal 2014, 28(7):2915-2931.
29. Christensen H., Hermann M. Immunological response as a source to variability in drug metabolism and transport. Frontiers in Pharmacology 2012, 3:8.
30. Christmas P., Carlesso N., Shang H., Cheng S.-M., Weber B.M., Preffer F.I., et al. Myeloid expression of cytochrome P450 4F3 is determined by a lineage-specific alternative promoter. The Journal of Biological Chemistry 2003, 278(27):25133-25142.
31. Christmas P., Jones J.P., Patten C.J., Rock D.A., Zheng Y., Cheng S.-M., et al. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. The Journal of Biological Chemistry 2001, 276(41):38166-38172.
32. 4 ω-1/ω-2 hydroxylase in mouse polymorphonuclear leukocytes. The Journal of Biological Chemistry 2006, 281(11):7189-7196.
33. Corcos L., Lucas D., Le Jossic-Corcos C., Dreano Y., Simon B., Plee-Gautier E., et al. Human cytochrome P450 4F3: Structure, functions, and prospects. Drug Metabolism and Drug Interactions 2012, 27(2):63-71.
34. Costea I., Mack D.R., Israel D., Morgan K., Krupoves A., Seidman E., et al. Genes involved in the metabolism of poly-unsaturated fatty-acids (PUFA) and risk for Crohn's disease in children & young adults. PLoS One 2010, 5(12). e15672.
35. Curley C.R., Monsuur A.J., Wapenaar M.C., Rioux J.D., Wijmenga C. A functional candidate screen for coeliac disease genes. European Journal of Human Genetics 2006, 14(11):1215-1222.
36. Dallas S., Sensenhauser C., Batheja A., Singer M., Markowska M., Zakszewski C., et al. De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes. Current Drug Metabolism 2012, 13(7):923-929.
37. Deng Y., Edin M.L., Theken K.N., Schuck R.N., Flake G.P., Kannon M.A., et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. The FASEB Journal 2011, 25(2):703-713.
38. Deng Y., Theken K.N., Lee C.R. Cytochrome P450 epoxygenases, soluble epoxide hydrolase and the regulation of cardiovascular inflammation. Journal of Molecular and Cellular Cardiology 2010, 48(2):331-341.
39. Dickmann L.J., McBride H.J., Patel S.K., Miner K., Wienkers L.C., Slatter J.G. Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression. Biochemical Pharmacology 2012, 83(12):1682-1689.
40. Dickmann L.J., Patel S.K., Rock D.A., Wienkers L.C., Slatter J.G. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metabolism and Disposition 2011, 39(8):1415-1422.
41. Dickmann L.J., Patel S.K., Wienkers L.C., Slatter J.G. Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Current Drug Metabolism 2012, 13(7):930-937.
42. 4 inactivation pathway in human and mouse skin cells. Archives of Biochemistry and Biophysics 2009, 484(1):80-86.
43. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England Journal of Medicine 1986, 315(26):1650-1659.
44. Edson K.Z., Rettie A.E. CYP4 enzymes as potential drug targets: Focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities. Current Topics in Medicinal Chemistry 2013, 13(12):1429-1440.
45. Elshenawy O.H., Anwar-Mohamed A., El-Kadi A.O. 20-Hydroxyeicosatetraenoic acid is a potential therapeutic target in cardiovascular diseases. Current Drug Metabolism 2013, 14(6):706-719.
46. Evers R., Dallas S., Dickmann L.J., Fahmi O.A., Kenny J.R., Kraynov E., et al. Critical review of preclinical approaches to investigate cytochrome P450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: A white paper. Drug Metabolism and Disposition 2013, 41(9):1598-1609.
47. Fan F., Muroya Y., Roman R.J. Cytochrome P450 eicosanoids in hypertension and renal disease. Current Opinion in Nephrology and Hypertension 2015, 24(1):37-46.
48. Fischer R., Konkel A., Mehling H., Blossey K., Gapelyuk A., Wessel N., et al. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. The Journal of Lipid Research 2014, 55(6):1150-1164.
49. Fleming I. The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease. Pharmacological Reviews 2014, 66(4):1106-1140.
50. Frye R.F., Schneider V.M., Frye C.S., Feldman A.M. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. Journal of Cardiac Failure 2002, 8(5):315-319.
51. Gandhi A., Moorthy B., Ghose R. Drug disposition in pathophysiological conditions. Current Drug Metabolism 2012, 13(9):1327-1344.
52. Gebremedhin D., Lange A.R., Lowry T.F., Taheri M.R., Birks E.K., Hudetz A.G., et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circulation Research 2000, 87(1):60-65.
53. Greenberg A.S., Obin M.S. Obesity and the role of adipose tissue in inflammation and metabolism. The American Journal of Clinical Nutrition 2006, 83(2):461S-465S.
54. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144(5):646-674.
55. Hardwick J.P., Eckman K., Kwang Lee Y., Abdelmegeed M.A., Esterle A., Chilian W.M., et al. Eicosanoids in metabolic syndrome. Advances in Pharmacology 2013, 66:157-266.
56. Harmon S.D., Fang X., Kaduce T.L., Hu S., Raj Gopal V., Falck J.R., et al. Oxygenation of omega-3 fatty acids by human cytochrome P450 4F3B: Effect on 20-hydroxyeicosatetraenoic acid production. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2006, 75(3):169-177.
57. Harvey R.D., Morgan E.T. Cancer, inflammation, and therapy: Effects on cytochrome P450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clinical Pharmacology & Therapeutics 2014, 96(4):449-457.
58. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140(6):900-917.
59. 4 metabolism in colonic mucosa with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 1995, 30(1):44-49.
60. Imig J.D. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiological Reviews 2012, 92(1):101-130.
61. Imig J.D. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins & Other Lipid Mediators 2013, 104-105:2-7.
62. Imig J.D., Hammock B.D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular disease. Nature Reviews. Drug Discovery 2009, 8(10):794-805.
63. Imig J.D., Simpkins A.N., Renic M., Harder D.R. Cytochrome P450 eicosanoids and cerebral vascular function. Expert Reviews in Molecular Medicine 2011, 13. e7.
64. Ishizuka T., Cheng J., Singh H., Vitto M.D., Manthati V.L., Falck J.R., et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-κB activation and the production of inflammatory cytokines in human endothelial cells. The Journal of Pharmacology and Experimental Therapeutics 2008, 324(1):103-110.
65. Jiang H., Anderson G.D., McGiff J.C. Red blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP). Pharmacological Reports 2010, 62(3):468-474.
66. Jiang J.G., Chen C.L., Card J.W., Yang S., Chen J.X., Fu X.N. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Research 2005, 65(11):4707-4715.
67. Jiang J.G., Ning Y.G., Chen C., Ma D., Liu Z.J., Yang S., et al. Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Research 2007, 67(14):6665-6674.
68. Kacevska M., Mahns A., Sharma R., Clarke S.J., Robertson G.R., Liddle C. Extra-hepatic cancer represses hepatic drug metabolism via interleukin (IL)-6 signalling. Pharmaceutical Research 2013, 30(9):2270-2278.
69. 4 ω-hydroxylases in rat liver and kidney. FEBS Letters 2003, 555(2):236-242.
70. Kalsotra A., Du L., Wang Y., Ladd P.A., Kikuta Y., Duvic M., et al. Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways. The FASEB Journal 2008, 22(2):538-547.
71. Kalsotra A., Strobel H.W. Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism. Pharmacology & Therapeutics 2006, 112(3):589-611.
72. Kang J.X. Fat-1 transgenic mice: A new model for omega-3 research. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2007, 77(5-6):263-267.
73. Kawakami H., Ohtsuki S., Kamiie J., Suzuki T., Abe T., Terasaki T. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. Journal of Pharmaceutical Sciences 2011, 100(1):341-352.
74. Kelly E.J., Nakano M., Rohatgi P., Yarov-Yarovoy V., Rettie A.E. Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states. Molecular Interventions 2011, 11(2):124-132.
75. 4 omega-hydroxylase. The Journal of Biological Chemistry 1993, 268(13):9376-9380.
76. Kim S., Ostor A.J., Nisar M.K. Interleukin-6 and cytochrome-P450, reason for concern?. Rheumatology International 2012, 32(9):2601-2604.
77. Kim D.H., Vanella L., Inoue K., Burgess A., Gotlinger K., Manthati V.L., et al. Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγ. Stem Cells and Development 2010, 19(12):1863-1873.
78. Kinloch R.D., Lee C.-M., van Rooijen N., Morgan E.T. Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen. Biochemical Pharmacology 2011, 82(3):312-321.
79. Kraemer M.J., Furukawa C.T., Koup J.R., Shapiro G.G., Pierson W.E., Bierman C.W. Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982, 69(4):476-480.
80. Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of CYP4F2 and CYP4A11. The Journal of Biological Chemistry 2000, 275(6):4118-4126.
81. Li R., Xu X., Chen C., Wang Y., Gruzdev A., Zeldin D.C., et al. CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ. American Journal of Physiology. Endocrinology and Metabolism 2015, 308(4):E270-E282.
82. Libby P. Inflammation and cardiovascular disease mechanisms. The American Journal of Clinical Nutrition 2006, 83(2):456S-460S.
83. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutrition Reviews 2007, 65(12):S140-S146.
84. Ling S., Jamali F. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: A drug-disease and drug-drug interaction. Basic & Clinical Pharmacology & Toxicology 2009, 105(1):24-29.
85. Liu Y., Zhang Y., Schmeizer K., Lee T.-S., Fang X., Zhu Y., et al. The anti-inflammatory effect of laminar flow: The role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(46):16747-16752.
86. Liu X., Zhao Y., Wang L., Yang X., Zheng Z., Zhang Y., et al. Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Kidney International 2009, 75(12):1288-1296.
87. Lopez-Vicario C., Alcaraz-Quiles J., Garcia-Alonso V., Rius B., Hwang S.H., Titos E., et al. Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides. Proceedings of the National Academy of Sciences of the United States of America 2015, 112(2):536-541.
88. Lustig R.H. Fructose: It's "alcohol without the buzz". Advances in Nutrition 2013, 4(2):226-235.
89. Lutz U., Bittner N., Ufer M., Lutz W.K. Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2010, 878(1):97-101.
90. Manhiani M., Quigley J.E., Knight S.F., Tasoobshirazi S., Moore T., Brands M.W., et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. American Journal of Physiology. Renal Physiology 2009, 297(3):F740-F748.
91. Moreno J.J. New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochemical Pharmacology 2009, 77(1):1-10.
92. Morgan E.T. Regulation of cytochromes P450 during inflammation and infection. Drug Metabolism Reviews 1997, 29(4):1129-1188.
93. Morgan E.T. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clinical Pharmacology & Therapeutics 2009, 85(4):434-438.
94. Murphy R.C., Gijon M.A. Biosynthesis and metabolism of leukotrienes. Biochemical Journal 2007, 405(3):379-395.
95. Nathan C. Points of control in inflammation. Nature 2002, 420(6917):846-852.
96. Nguyen T.V., Ukairo O., Khetani S.R., McVay M., Kanchagar C., Seghezzi W., et al. Establishment of a hepatocyte-Kupffer cell co-culture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metabolism and Disposition 2015, 43(5):774-785.
97. Nithipatikom K., Gross E.R., Endsley M.P., Moore J.M., Isbell M.A., Falck J.R., et al. Inhibition of cytochrome P450ω-hydroxylase. A novel endogenous cardioprotective pathway. Circulation Research 2004, 95(8):e65-e71.
98. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285(5431):1276-1279.
99. Nyagode B.A., Jahangardi R., Merrell M.D., Tansey M.G., Morgan E.T. Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions. Pharmacology Research & Perspectives 2014, 2(1). e00027.
100. Nyagode B.A., Lee C.-M., Morgan E.T. Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-γ-null mice. The Journal of Pharmacology and Experimental Therapeutics 2010, 335(2):480-488.
101. Oni-Orisan A., Alsaleh N., Lee C.R., Seubert J.M. Epoxyeicosatrienoic acids and cardioprotection: The road to translation. Journal of Molecular and Cellular Cardiology 2014, 74:199-208.
102. Panigrahy D., Edin M.L., Lee C.R., Huang S., Bielenberg D.R., Butterfield C.E., et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. The Journal of Clinical Investigation 2012, 122(1):178-191.
103. Panigrahy D., Greene E.R., Pozzi A., Wang D.W., Zeldin D.C. EET signaling in cancer. Cancer and Metastasis Reviews 2011, 30(3-4):525-540.
104. Panigrahy D., Kalish B.T., Huang S., Bielenberg D.R., Le H.D., Yang J., et al. Epoxyeicosanoids promote organ and tissue regeneration. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(33):13528-13533.
105. Patel N.S., Cuzzocrea S., Chatterjee P.K., Di Paola R., Sautebin L., Britti D., et al. Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. Molecular Pharmacology 2004, 66(2):220-227.
106. Pillarisetti S., Khanna I. Targeting soluble epoxide hydrolase for inflammation and pain-An overview of pharmacology and the inhibitors. Inflammation & Allergy Drug Targets 2012, 11(2):143-158.
107. Piquette-Miller M., Jamali F. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metabolism and Disposition 1995, 23(2):240-245.
108. Plee-Gautier E., Antoun J., Goulitquer S., Le Jossic-Corcos C., Simon B., Amet Y., et al. Statins increase cytochrome P450 4F3-mediated eicosanoids production in human liver cells: A PXR dependent mechanism. Biochemical Pharmacology 2012, 84(4):571-579.
109. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nature Reviews. Immunology 2007, 7(10):803-815.
110. Pozzi A., Popescu V., Yang S., Mei S., Shi M., Puolitaival S.M., et al. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. The Journal of Biological Chemistry 2010, 285(17):12840-12850.
111. Renton K.W. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Current Drug Metabolism 2004, 5(3):235-243.
112. Richardson T.A., Sherman M., Antonovic L., Kardar S.S., Strobel H.W., Kalman D., et al. Hepatic and renal cytochrome P450 gene regulation during Citrobacter rodentium infection in wildtype and Toll-like receptor 4 mutant mice. Drug Metabolism and Disposition 2006, 34(3):354-360.
113. Rivory L.P., Slaviero K.A., Clarke S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer 2002, 87(3):277-280.
114. Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25(11):1679-1691.
115. Rubin K., Janefeldt A., Andersson L., Berke Z., Grime K., Andersson T.B. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes. Drug Metabolism and Disposition 2015, 43(1):119-125.
116. Schmeizer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(28):9772-9777.
117. Schmitt C., Kuhn B., Zhang X., Kivitz A.J., Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clinical Pharmacology & Therapeutics 2011, 89(5):735-740.
118. Schuck R.N., Theken K.N., Edin M.L., Caughey M., Bass A., Ellis K., et al. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis 2013, 227(2):442-448.
119. Schuck R.N., Zha W., Edin M.L., Gruzdev A., Vendrov K.C., Miller T.M., et al. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One 2014, 9(10). e110162.
120. Sehgal N., Agarwal V., Valli R.K., Joshi S.D., Antonovic L., Strobel H.W., et al. Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation. Biochemical Pharmacology 2011, 82(1):53-64.
121. Shahabi P., Siest G., Meyer U.A., Visvikis-Siest S. Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders. Pharmacology & Therapeutics 2014, 144(2):134-161.
122. Shahabi P., Siest G., Visvikis-Siest S. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids. Drug Metabolism Reviews 2014, 46(1):33-56.
123. 4 in human polymorphonuclear leukocytes. The Journal of Biological Chemistry 1984, 259(16):10181-10187.
124. Shedlofsky S.I., Israel B.C., McClain C.J., Hill D.B., Blouin R.A. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. The Journal of Clinical Investigation 1994, 94(6):2209-2214.
125. Shin K.H., Choi M.H., Lim K.S., Yu K.S., Jang I.J., Cho J.Y. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clinical Pharmacology & Therapeutics 2013, 94(5):601-609.
126. Siest G., Jeannesson E., Marteau J.B., Samara A., Pfister M., Visvikis-Siest S. Drug metabolizing enzymes and transporters mRNA in peripheral blood mononuclear cells of healthy subjects: Biological variations and importance of pre-analytical steps. Current Drug Metabolism 2009, 10(4):410-419.
127. Simopoulos A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Experimental Biology and Medicine 2008, 233(6):674-688.
128. Slaviero K.A., Clarke S.J., Rivory L.P. Inflammatory response: An unrecognized source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncology 2003, 4(4):224-232.
129. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(6):2186-2191.
130. Sodhi K., Inoue K., Gotlinger K.H., Canestraro M., Vanella L., Kim D.H., et al. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. Journal of Pharmacology and Experimental Therapeutics 2009, 331(3):906-916.
131. Spector A.A., Kim H.Y. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism. Biochimica et Biophysica Acta 2015, 1851(4):356-365.
132. Stoilov I., Krueger W., Mankowski D., Guernsey L., Kaur A., Glynn J., et al. The cytochromes P450 (CYP) response to allergic inflammation of the lung. Archives of Biochemistry and Biophysics 2006, 456(1):30-38.
133. Straub R.H. Insulin resistance, selfish brain, and selfish immune system: An evolutionarily positively selected program used in chronic inflammatory diseases. Arthritis Research & Therapy 2014, 16(Suppl. 2):S4.
134. Sudhahar V., Shaw S., Imig J.D. Epoxyeicosatrienoic acid analogs and vascular function. Current Medicinal Chemistry 2010, 17(12):1181-1190.
135. Sun C.W., Falck J.R., Harder D.R., Roman R.J. Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 1999, 33(1):414-418.
136. Sunman J.A., Hawke R.L., LeCluyse E.L., Kashuba A.D.M. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metabolism and Disposition 2004, 32(3):359-363.
137. Tanaka T., Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunology Research 2014, 2(4):288-294.
138. Theken K.N., Deng Y., Kannon M.A., Miller T.M., Poloyac S.M., Lee C.R. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metabolism and Disposition 2011, 39(1):22-29.
139. Theken K.N., Schuck R.N., Edin M.L., Tran B., Ellis K., Bass A., et al. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 2012, 222(2):530-536.
140. Vainio P., Gupta S., Ketola K., Mirtti T., Mpindi J.-P., Kohonen P., et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. The American Journal of Pathology 2011, 178(2):525-536.
141. Wang Y.X., Ulu A., Zhang L.N., Hammock B. Soluble epoxide hydrolase in atherosclerosis. Current Atherosclerosis Reports 2010, 12(3):174-183.
142. 4 levels after traumatic brain injury. Journal of Neurotrauma 2008, 25(10):1187-1194.
143. Wei X., Zhang D., Dou X., Niu N., Huang W., Bai J., et al. Elevated 14,15-epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer 2014, 14:841.
144. 4 metabolism in CYP4F18-deficient mice does not impact inflammation following renal ischemia. Biochimica et Biophysica Acta 2014, 1841(6):868-879.
145. Wu C.C., Gupta T., Garcia V., Ding Y., Schwartzman M.L. 20-HETE and blood pressure regulation: Clinical implications. Cardiology in Review 2014, 22(1):1-12.
146. Xu X., Tu L., Feng W., Ma B., Li R., Zheng C., et al. CYP2J3 gene delivery up-regulated adiponectin expression via reduced endoplasmic reticulum stress in adipocytes. Endocrinology 2013, 154(5):1743-1753.
147. Yang K.H., Lee M.G. Effects of endotoxin derived from Escherichia coli lipopolysaccharide on the pharmacokinetics of drugs. Archives of Pharmacal Research 2008, 31(9):1073-1086.
148. Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 2013, 138(1):103-141.
149. Zhang G., Kodani S., Hammock B.D. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Progress in Lipid Research 2014, 53:108-123.
150. Zhang W., Yang A.L., Liao J., Li H., Dong H., Chung Y.T., et al. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice. Digestive Diseases and Sciences 2012, 57(10):2580-2591.
151. Zordoky B.N., El-Kadi A.O. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Current Drug Metabolism 2009, 10(2):164-178.